DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Anus Laboratories Ltd

532981·BSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

N/A

P/E Ratio

N/A

P/B Ratio

N/A

EPS

₹0.14

Book Value

₹6.77

ROE

2.28%Weak

ROCE

12.00%Decent

Dividend Yield

N/A

Debt / Equity

N/A

Face Value

₹1.00

52W High

N/A

52W Low

N/A

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Expensive

None moatMedium uncertainty

Fair value estimate

₹6

No recent traded price

BearFair valueBull

₹5₹6₹7

/100

Business quality — Watch the fundamentals

Growth 50Profitability 0Efficiency 20Valuation 50

Plain English

Our view

A steady, established business
Promoters hold a controlling stake
Weak returns on equity (2%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

2.3%Weak

Above 15% is considered healthy for Indian equities

ROCE

12.0%Decent

Above 18% means capital is working hard

Debt/Eq

—

Mkt Cap

—

P/B

—

EPS

₹0.14

Div Yield

—

What changed

Recent changes

Foreign investors-1.7% stake last quarter
Domestic institutions+2.7% stake last quarter
Promoters+1.27% stake last quarter

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Strong

+18% rev CAGR

Profitability

Modest

2.3% ROE

Financial health

N/A

No debt data

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+18.2%

+19.7%

10Y

—

Profit

-42.8%

-26.5%

10Y

—

EPS

-40.7%

—

10Y

—

Profile

Pros

Stock is trading at 0.04 times its book value

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has low interest coverage ratio.
Company has a low return on equity of 8.50% over last 3 years.
Dividend payout has been low at 3.80% of profits over last 3 years
Company's cost of borrowing seems high

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Dec 2025

Promoters raised their stake by 1.27 pts; foreign investors sold 1.74 pts; domestic institutions added 2.72 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

52%

Promoter

Promoters

52.4%+1.27

Public

16.9%-2.27

FII / FPI

7.8%-1.74

DII

22.8%+2.72

Total shareholders

1,19,560+3,705 QoQ

Quarterly trend

Ownership over time

Q3 FY26

Promoter52.41%

FII7.81%

DII22.83%

Public16.93%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Anu's Laboratories Limited manufactures and supplies drug intermediates and related products for the pharmaceutical industry.